IDO1 and hepatocellular carcinoma: To evaluate the influence of LINC01116 on ICB therapy in HCC, we performed a correlation analysis between LINC01116 and immune checkpoint targets (CTLA4, TIM-3, PD-L1, PD-L2, PD-1, IDO1, GITR, HDAC2, B7-H3, and VISTA) and found positive correlations with the levels of all 10 targets (Figure 10B).